degranulation


Also found in: Dictionary, Wikipedia.

de·gran·u·la·tion

(dē-gran'yū-lā'shŭn),
Disappearance or loss of cytoplasmic granules from a cell or activation of granulocytic cells (for example, neutrophils, mast cells, basophils, eosinophils).

degranulation

(dē-grăn′yə-lā′shən)
n.
The process of losing granules.
References in periodicals archive ?
Due to the relatively benign course of cutaneous mastocytosis, the mainstay of treatment is focused on minimizing mast cell degranulation to control subsequent symptoms.
Moreover, the PGLYRP1 dimer in human serum and polymorphonuclear cells is detected, from where it is secreted after degranulation; these cells being a possible source of serum PGLYRP1; these cells being a possible source of serum PGLYRP1.
A previous study by Theoharides and colleagues showed that restraint stress alone may cause mast cell degranulation in rat brains through stimulation of the hypothalamic-pituitary-adrenal axis (Theoharides et al., 1995).
"Even for the difficult-to-treat subpopulations of CSU, ligelizumab appears to be a drug that can protect against mast cell degranulation. We see a reduction in angioedema activity; we see a reduction in wheal size and number; we see a reduction in the itch--so across all the symptoms in the difficult subpopulations, this is the better drug.
Then, stress-induced TRPA1 activation and concomitant neuropeptides SP released from afferent nerve endings which can directly stimulate MC, and cause MC mediator release, as well as alter function by piecemeal- or classic degranulation (24).
To induce degranulation of mast cells in the dura mater, we applied to the dura mater compound 48/80 which is known as a mast cell degranulating agent an IgE-independent manner (24).
Clinically, it has also been reported that in asthmatic patients, the released IgE are cross-linked with a FcIuR receptor on mast cell surface which resulted in its degranulation.43 This mast cell degranulation was further associated with the release of pro-inflammatory cytokines including tumor necrosis factor-[alpha] (TNF-[alpha]), IL-4 and IL-6.44-46 Furthermore, IgG1 was reported to form a complex with an inhaled allergen which further aggravated Th2 response.47
In addition, PRF slows down the blood activation process which could induce an increased leukocyte degranulation and cytokine release from pro-inflammatory mediators such as interleukin (IL)-1[beta], IL-6 and tumour necrosis factor-[alpha] to anti-inflammatory cytokines such as IL-4, different growth factors like transforming growth factor-1[beta], platelet derived growth factor-[alpha] [beta], and vascular endothelial growth factor and glycoproteins (thrombospondin-1) over more than 7 days.
Based on this recommendation, further studies have included additional histological criteria like eosinophilic abscesses, degranulation, and basal zone hyperplasia or biomarker staining for eosinophil degranulation products like major basic protein and interleukins.
Mast cell activation syndrome (MCAS) is a condition in which patients experience recurrent and episodic symptoms of mast cell degranulation. Patients with this disorder appear to represent a growing proportion of the mast cell disorder patient population [1,2].
Stimulation of mast cells presents the antigen to the T cells which in sequence causes activation and degranulation of mast cell and release of various factors like TNF-[alpha], a series of interleukins (IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-11, IL-13, and IL-16), chymase, and tryptase.